Preliminary Data Suggest PFS Benefit With Personalized Neoantigen Cancer Vaccine In Patients With Metastatic MSS-CRC

OncLive (4/2, Seymour) reports, “The addition of the personalized neoantigen cancer vaccine GRANITE (GRT-C901/GRT-R902) to maintenance therapy with ipilimumab (Yervoy) and atezolizumab (Tecentriq) plus 5-flourouracil (5-FU) and bevacizumab (Avastin) following induction therapy with FOLFOX or FOLFOXIRI plus bevacizumab showed an early trend in progression-free survival (PFS) benefit vs induction therapy followed by maintenance 5-FU and bevacizumab alone in patients with metastatic microsatellite stable colorectal cancer (MSS-CRC), according to topline data from the ongoing phase 2 portion of a phase 2/3 study.” The findings were published in a press release. Cancer Network (4/2, Conroy) reports “a trend in improved PFS with the vaccine combination was reported among those with high-risk disease, which included a median PFS of 12 months in the experimental arm vs 7 months in the control arm.”